The concept of biological vaccine rose sharply on the 20th. As of press time, Cansino Biologics Inc(688185) soared by more than 15%, once approaching the daily limit Changchun Bcht Biotechnology Co(688276) , Shanghai Pharmaceuticals Holding Co.Ltd(601607) increased by more than 7%, and Shandong Sinobioway Biomedicine Co.Ltd(002581) , Hualan Biological Engineering Inc(002007) , Changchun High And New Technology Industries (Group) Inc(000661) , Hualan vaccine, Shenzhen Kangtai Biological Products Co.Ltd(300601) , etc. increased by more than 5%.
Cansino Biologics Inc(688185) may 19 announcement: the World Health Organization (hereinafter referred to as "who") disclosed on its official website on May 19, 2022 that the company's recombinant novel coronavirus vaccine (adenovirus type 5 vector) kweisa (hereinafter referred to as "the product") was included in the "emergency use listing" (hereinafter referred to as "Eul").
The product is constructed by genetic engineering method. With replication defective human type 5 adenovirus as the vector, it can express the S antigen of novel coronavirus. It is intended to prevent diseases caused by novel coronavirus infection. At the same time, it does not contain preservatives, adjuvants and ingredients of animal origin.
The company disclosed that the Eul procedure assessed the applicability of new health products in public health emergencies. Its purpose is to provide drugs, vaccines and diagnostic methods as soon as possible in response to emergencies, while respecting strict safety, efficacy and quality standards. The assessment process should weigh the threat posed by the emergency, the benefits of using the product and any potential risks. At the same time, who-ul is a prerequisite for providing vaccines for the covid-19 vaccine implementation plan (covax). The list also allows countries to accelerate their regulatory approvals to import and manage covid-19 vaccines.
The decision to include kweisa in Eul is based on the review of the product's quality, safety, effectiveness data and risk management plan (RMP) by who prequalification (PQ) experts, including regulatory experts from around the world. The final risk benefit assessment is conducted by the Eul technical advisory group (tag).
Cansino Biologics Inc(688185) said that after the product is included in who Eul, the company still needs to conduct commercial negotiations with the intended countries on the future sales of the product. If the subsequent overseas countries increase the purchase and use of the product, it will have a certain positive impact on the performance of the listed company.
The company also indicated that with the efforts of the World Health Organization (who) and countries around the world, the global covid-19 vaccination population will increase rapidly in 2021 and is expected to maintain an upward trend in 2022. However, it will be more difficult to promote covid-19 vaccination in the future, and the growth rate of global covid-19 vaccination rate will gradually slow down. With the development of the epidemic situation, the market of vid-19 vaccine will become more competitive, and the sales of vid-19 vaccine will be affected by more factors in the future.
According to the information released on Cansino Biologics Inc(688185) official website, up to now, kvisa Cansino Biologics Inc(688185) biological covid-19 vaccine has obtained emergency use authorization or conditional listing approval from more than 10 countries, including China, Pakistan, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Indonesia, United Arab Emirates and Malaysia. At the same time, Cansino Biologics Inc(688185) bio has also cooperated with Mexico, Pakistan and Malaysia to establish filling production lines, realize the localized production of covid-19 vaccine and make a new breakthrough in anti epidemic cooperation. Based on its good clinical trial results, Cansino Biologics Inc(688185) biological covid-19 vaccine has been approved as a sequential booster vaccine in China, Argentina, Malaysia and Indonesia. At present, the company has established a mature commercial service network and efficient and safe supply and distribution system in China, Southeast Asia, the Middle East, Latin America and other countries and regions.
In addition, Cansino Biologics Inc(688185) biological is actively laying out the mRNA R & D and industrialization platform, and its application for clinical trial of novel coronavirus mRNA vaccine has been approved by the State Drug Administration. As one of the five core technology platforms of Cansino Biologics Inc(688185) biology, mRNA technology has a wide range of applications, which can shorten the product development time, quickly realize the industrialization of scientific research achievements, and benchmark the international biomedical enterprises at the forefront in this field.
Dongguan Securities pointed out that there are still many covid-19 vaccines under development in China, mainly focusing on three technical paths: mRNA, recombinant protein and virus vector. The research and development of covid-19 virus vaccine in China has always been in the first place in the world. At present, many covid-19 vaccine pipelines in China have entered the late stage of clinical research. With the advancement of covid-19 vaccine research, the types of covid-19 vaccines in China will be more abundant in the future, which can provide more choices for the sequential booster vaccination of covid-19 vaccine.
The agency said that studies have shown that covid-19 vaccine can reduce the severe rate and mortality caused by Omicron, and covid-19 vaccine is still an important means of epidemic prevention. It is suggested to pay attention to Chongqing Zhifei Biological Products Co.Ltd(300122) and Cansino Biologics Inc(688185) , which have been approved for sequential booster vaccination in China; Several covid-19 vaccine pipelines are arranged, and the mRNA vaccine under development is expected to be the first approved Walvax Biotechnology Co.Ltd(300142) in China .
